Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 17Other 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1Breast Diseases 1

Interventions

Cisplatin 30pembrolizumab 24Magnetic Resonance Spectroscopy 24Specimen Handling 20Cetuximab 18Nivolumab 15Carboplatin 14Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Radiotherapy, Intensity-Modulated 11Radiotherapy 10Radiation 9Paclitaxel 9Docetaxel 8Biopsy 8Immunoglobulin G 7Disulfides 7Surveys and Questionnaires 6Ipilimumab 6atezolizumab 5Fluorouracil 5toripalimab 4dostarlimab 4cemiplimab 4cabozantinib 4Taxes 4Gemcitabine 4CTLA-4 Antigen 4Bevacizumab 4(225)Ac-DOTA-c(RGDyK) 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
exemestane × Head & Neck × 30 days × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡